230 related articles for article (PubMed ID: 32451067)
21. MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma.
van Velzen MJM; Derks S; van Grieken NCT; Haj Mohammad N; van Laarhoven HWM
Cancer Treat Rev; 2020 Jun; 86():102024. PubMed ID: 32388292
[TBL] [Abstract][Full Text] [Related]
22. Targeting the complexity of ERBB2 biology in gastroesophageal carcinoma.
Augustin JE; Soussan P; Bass AJ
Ann Oncol; 2022 Nov; 33(11):1134-1148. PubMed ID: 35963482
[TBL] [Abstract][Full Text] [Related]
23. Evolving treatments for advanced gastric cancer: appraisal of the survival trend.
Roberto M; Romiti A; Onesti CE; Zullo A; Falcone R; Marchetti P
Expert Rev Anticancer Ther; 2016 Jul; 16(7):717-29. PubMed ID: 27137418
[TBL] [Abstract][Full Text] [Related]
24. Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough.
Weinberg BA; Xiu J; Hwang JJ; Shields AF; Salem ME; Marshall JL
Oncologist; 2018 Oct; 23(10):1171-1177. PubMed ID: 29703766
[TBL] [Abstract][Full Text] [Related]
25. A systematic review of HER2 blockade for the curative treatment of gastroesophageal adenocarcinoma: Successes achieved and opportunities ahead.
Stroes CI; van den Ende T; Derks S; van Laarhoven HWM
Cancer Treat Rev; 2021 Sep; 99():102249. PubMed ID: 34171733
[TBL] [Abstract][Full Text] [Related]
26. Cooperation between chemotherapy and immunotherapy in gastroesophageal cancers.
Davern M; Lysaght J
Cancer Lett; 2020 Dec; 495():89-99. PubMed ID: 32950619
[TBL] [Abstract][Full Text] [Related]
27. The safety and efficacy of anti-PD-1/anti-PD-L1 antibody therapy in the treatment of previously treated, advanced gastric or gastro-oesophageal junction cancer: A meta-analysis of prospective clinical trials.
Ni X; Xing Y; Sun X; Suo J
Clin Res Hepatol Gastroenterol; 2020 Apr; 44(2):211-222. PubMed ID: 31208922
[TBL] [Abstract][Full Text] [Related]
28. Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease.
Catenacci DVT; Moya S; Lomnicki S; Chase LM; Peterson BF; Reizine N; Alpert L; Setia N; Xiao SY; Hart J; Siddiqui UD; Hogarth DK; Eng OS; Turaga K; Roggin K; Posner MC; Chang P; Narula S; Rampurwala M; Ji Y; Karrison T; Liao CY; Polite BN; Kindler HL
Cancer Discov; 2021 Feb; 11(2):308-325. PubMed ID: 33234578
[TBL] [Abstract][Full Text] [Related]
29. Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial.
Doi T; Iwasa S; Muro K; Satoh T; Hironaka S; Esaki T; Nishina T; Hara H; Machida N; Komatsu Y; Shimada Y; Otsu S; Shimizu S; Watanabe M
Gastric Cancer; 2019 Jul; 22(4):817-827. PubMed ID: 30515672
[TBL] [Abstract][Full Text] [Related]
30. Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives.
Taieb J; Moehler M; Boku N; Ajani JA; Yañez Ruiz E; Ryu MH; Guenther S; Chand V; Bang YJ
Cancer Treat Rev; 2018 May; 66():104-113. PubMed ID: 29730461
[TBL] [Abstract][Full Text] [Related]
31. From Tumor Immunology to Immunotherapy in Gastric and Esophageal Cancer.
Vrána D; Matzenauer M; Neoral Č; Aujeský R; Vrba R; Melichar B; Rušarová N; Bartoušková M; Jankowski J
Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30577521
[TBL] [Abstract][Full Text] [Related]
32. Advances in Immunotherapy in Esophagogastric Cancer.
Jazieh K; Yoon H; Zhu M
Hematol Oncol Clin North Am; 2024 Jun; 38(3):599-616. PubMed ID: 38493074
[TBL] [Abstract][Full Text] [Related]
33. PTEN loss is associated with a poor response to trastuzumab in HER2-overexpressing gastroesophageal adenocarcinoma.
Deguchi Y; Okabe H; Oshima N; Hisamori S; Minamiguchi S; Muto M; Sakai Y
Gastric Cancer; 2017 May; 20(3):416-427. PubMed ID: 27517839
[TBL] [Abstract][Full Text] [Related]
34. HER2 testing in gastric and gastroesophageal junction cancers: a new therapeutic target and diagnostic challenge.
Hicks DG; Whitney-Miller C
Appl Immunohistochem Mol Morphol; 2011 Dec; 19(6):506-8. PubMed ID: 22089490
[TBL] [Abstract][Full Text] [Related]
35. Back from the Brink: EGFR Inhibition in Gastroesophageal Cancer.
Openshaw MR; Pinato DJ; Valeri N
Clin Cancer Res; 2021 Jun; 27(11):2964-2966. PubMed ID: 33771852
[TBL] [Abstract][Full Text] [Related]
36. First Report of Dramatic Tumor Responses with Ramucirumab and Paclitaxel After Progression on Pembrolizumab in Two Cases of Metastatic Gastroesophageal Adenocarcinoma.
Chakrabarti S; Dong H; Paripati HR; Ross HJ; Yoon HH
Oncologist; 2018 Jul; 23(7):840-843. PubMed ID: 29674442
[TBL] [Abstract][Full Text] [Related]
37. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
38. PD-1 and PD-L1 inhibitors in oesophago-gastric cancers.
Akin Telli T; Bregni G; Camera S; Deleporte A; Hendlisz A; Sclafani F
Cancer Lett; 2020 Jan; 469():142-150. PubMed ID: 31669518
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapy in advanced gastric cancer, is it the future?
Coutzac C; Pernot S; Chaput N; Zaanan A
Crit Rev Oncol Hematol; 2019 Jan; 133():25-32. PubMed ID: 30661655
[TBL] [Abstract][Full Text] [Related]
40. Positioning of second-line treatment for advanced gastric and gastroesophageal junction adenocarcinoma.
Pericay C; Rivera F; Gomez-Martin C; Nuñez I; Cassinello A; Imedio ER
Cancer Med; 2016 Dec; 5(12):3464-3474. PubMed ID: 27774774
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
